Multiple development programs for cancer-specific peptide vaccines, with partners including Shionogi & Co., Ltd., Otsuka Pharmaceutical Co., Ltd. and Ono Pharmaceutical Co., Ltd. leading clinical development. The company is strengthening its supporting and back-office role and advancing clinical development and commercialization through partnerships.